TheraRadar
Data updated: May 26, 2026

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE (donepezil hydrochloride)

CNS Approved 2017-01-27

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE is indicated for the treatment of Alzheimer's Disease.

Source: FDA Label • ANI PHARMS

How MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE Works

This combination product utilizes two distinct mechanisms to address the symptoms of Alzheimer's disease. Memantine acts as an uncompetitive NMDA receptor antagonist that binds to receptor-operated cation channels to manage the persistent activation of these receptors by glutamate. Donepezil enhances cholinergic function by reversibly inhibiting acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine. This inhibition increases the concentration of acetylcholine in the central nervous system to improve neurotransmission.

3
Indications
--
Phase 3 Trials
9
Years on Market

Details

Status
Prescription
First Approved
2017-01-27
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE Approval History

2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
13 FDA actions from 2017 to 2025
Jul 2025 ORIGINAL
Update
Feb 2025 SUPPL
Mfg · Manufacturing (CMC)
Dec 2023 ORIGINAL
Update

What MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE Treats

1 indications

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE is approved for 1 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Alzheimer's Disease
Source: FDA Label

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Direct competitors

1

Same target(s) AND same indication — head-to-head.

MoA expansion candidates

3

Same target(s), different indications — where else is this mechanism being explored?

Unlock 7 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

3 of 10

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMYVID
FLORBETAPIR F-18
1 shared
AVID RADIOPHARMS INC
Shared indications:
ARICEPT
DONEPEZIL HYDROCHLORIDE
1 shared
EISAI INC
Shared indications:
EXELON
RIVASTIGMINE TARTRATE
1 shared
Novartis
Shared indications:
📋

Clinical Trial Registry

11 trials
Trial Sponsor ID Phase Status Title
NCT00688376 results posted E2020-G000-333 E2020-G000-334, 2007-005435-28 Ph 3 completed Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
NCT01466270 results posted IRB00019792-1 U10CA081851, REBACCCWFU 97211 Ph 2 completed Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction
NCT00369785 results posted IRB00000551 U10CA081851, REBACCCWFU 91105 Ph 3 completed Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
NCT04013477 DA5207_ADK_Ia Ph 1 completed Single-ascending Dose Phase 1 Clinical Trial to Evaluate the Safety and PK of DA-5207 TDS in Healthy Adults
NCT02660983 results posted E2020-K082-418 Ph 4 completed A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
NCT01903824 C26401/1111 2013-001883-51 Ph 1 completed Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects
NCT00695136 results posted 080154 08-M-0154 Ph 1, Ph 2 completed The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism
NCT01506752 E2020-J081-034 Ph 1 completed A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males
NCT01506739 E2020-J081-033 Ph 1 completed A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males
NCT01504503 645/09 Ph 1 completed Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition
NCT01504516 646-09 Ph 1 completed Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE FDA Label Details

Indications & Usage

FDA Label (PDF)

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE is indicated for the treatment of Alzheimer's Disease.

Explore on TheraRadar

Alzheimer's Disease Drug Landscape 2026

Disease-modifying therapies, symptomatic treatments, and clinical trial intelligence

See insight

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.